Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
|
|
- Ada Webb
- 5 years ago
- Views:
Transcription
1 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Managing Anti-TB Therapy Side Effects and Complications Lisa Armitige, MD, PhD May 9, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant financial relationships with any commercial companies pertaining to this educational activity 1
2 TB Medications and Adverse Effects Lisa Armitige, MD, PhD Medical Consultant Heartland National TB Center Associate Professor of Internal Medicine and Peditarics Division of Infectious Diseases UT-Tyler HSC Objectives Describe the monitoring process for adverse drug events associated with anti-tb drugs Side effects and drug toxicities Recognizing the most common adverse effects of TB therapy Discuss the nursing interventions and medical management of the most common adverse drug events seen in patients on first-line antituberculosis therapy Case studies 2
3 Monitoring Process Ongoing process Begins with initial assessment Requires a food provider patient relationship Case management plan Patient Education Toxicity assessment Daily/BIW when administering DOT Monthly Drug Monitoring Goals Recognize adverse drug events Assess appropriately Intervene rapidly Prevent further morbidity/mortality Minimize treatment interruptions Reduce opportunities for medical mismanagement Avoid development of psychological intolerance Support adherence and the therapeutic relationship 3
4 Side Effects Unpleasant, but mild reactions No long lasting health effects Do not usually require changes in therapy -Gas Bloating Mild nausea Discoloration of body fluids Irritability Difficulty sleeping Photosensitivity Adverse Drug Reactions More serious May be life threatening Require modifying the dose/discontinuation of drug May require additional therapy and/or hospitalization Significant GI disturbances Hepatotoxicity Dermatologic and hypersensitivity reactions Ophthalmic toxicity CNS toxicity Neurotoxicity Ototoxicity Musculoskeletal adverse effects Renal toxicity 4
5 First-line Drugs Isoniazid (INH) Rifampin (RIF) Rifabutin Rifapentine Ethambutol (EMB) Pyrazinamide (PZA) Isoniazid GI upset Nausea Vomiting Loss of appetite Rash Mild CNS toxicity Peripheral neuropathy Tingling to fingers & toes Hepatotoxicity 5
6 Gastrointestinal Upset Common in the first few weeks of therapy Evaluate for other causes Give a light snack before meds Administer antiemetics Phenergan Zofran Isoniazid GI upset Nausea Vomiting Loss of appetite Rash Mild CNS toxicity Peripheral neuropathy Tingling to fingers & toes Hepatotoxicity 6
7 Hepatotoxicity Early Signs Fatigue Poor appetite Taste alteration Nausea Abdominal discomfort Bloating Minimal rash Later Signs Vomiting Abdominal pain Jaundice Change in color of urine and stool Changes in behavior, memory loss Most at Risk for Hepatotoxicity Underlying liver disease Hepatitis B and C Alcoholics Immediate (4 months) post-partum period Those on other hepatotoxic medications 7
8 Hepatotoxic Drugs Tylenol Tetracycline, erythromycin, others Dilantin Valproate Cholesterol lowering medications Antifungal drugs Glucose lowering drugs Valium Monitoring Establish rapport Take a good medical history Clarify preexisting conditions that may increase risk of hepatotoxicity: History of Hepatitis B or C History of other liver disease Take a good social history ETOH use (be specific) Educate patient of signs and symptoms of hepatotoxicity 8
9 Managing Hepatotoxicity Hold medications and repeat LFT s immediately Continue therapy ALT <5 x upper limit of normal and asymptomatic 20% of patients on standard therapy have asymptomatic elevation in LFT s Stop therapy ALT > 3 times upper limit of normal and symptomatic ALT > 5 times upper limit of normal and asymptomatic Hepatotoxicity Restarting therapy LFT s must be < 2 times upper limit of normal Rechanllege Medications Introduce one drug at a time Monitor enzymes carefully Stop therapy if symptomatic or increased enzymes and eliminate last drug added from regimen 9
10 Case Study # 1 - Hepatotoxicity 38 year old male diagnosed with Pulmonary TB while incarcerated. On Mar. 13, he started standard RIPE regimen. Baseline laboratory values were ALT 42, AST 63. On April 15, 1 month later, he was changed to BIW dosing. EMB was discontinued when susceptibility results showed isolate to be susceptible to INH/RIF. Patient was released from jail and continued medication on DOT by local health department. On June 4, 2½ months after starting anti TB therapy, follow-up lab results were ALT 304, AST 97. He was asymptomatic for hepatitis. Case Study # 1 - Hepatotoxicity What would be the next step for this patient with elevated LFT s? Take the following into consideration: Baseline LFT s : ALT 42, AST 63, Follow up LFT s : ALT 304, AST 97 (normal values: AST u/l, ALT u/l) 10
11 Normal values: AST: u/l ALT: ALT u/l Calculation Divide lab result by higher number of normal value AST 97/42 = 2.3 X ULN ALT 304/40 = 7.6 XULN Case Study #1- Hepatotoxicity What is the next step for this patient with elevated LFT s? Hold TB medications! ALT > 5 times upper limit of normal and asymptomatic ALT > 3 times upper limit of normal and symptomatic 11
12 Case Study #1 Hepatotoxicity When assessing this patient, what significant information is important for identifying if this patient is at risk for developing hepatotoxicity? Identify any underlying liver disease (hepatitis A, B, C) Identify if patient drinks any alcoholic beverages? Identify if patient is taking any other Hepatotoxic MEDICATIONS Case Study #1 Hepatotoxicity Anti-TB therapy was re-started by re-introducing one medication at a time when liver enzymes < 2 times upper limit of normal. Liver enzymes were monitored carefully. At a follow up appointment patient admitted to drinking 6-12 oz. beers almost every day with his neighbor What risk factors can you identify that place this patient at risk for developing hepatoxicity? He drinks 6-12 oz. beers almost every day with his neighbor. 12
13 Case Study #1- Hepatotoxicity How do we monitor him for the remainder of his treatment? Monitor closely/ monitor LFT s Re-educate patient to abstain from alcohol while on anti-tb medication Review adverse effects Encourage compliance Instruct patient to self monitor for side effects while on meds Consider a liver friendly regimen (Amikacin, levofloxacin, EMB) Most importantly: Instruct patient to stop taking TB medications immediately and seek medical attention if symptoms of hepatitis occur again. 13
14 Rifampin GI upset Nausea, vomiting loss of appetite Hepatotoxicity Thrombocytopenia, hemolytic anemia Bleeding Renal Toxicity Flu-like syndrome Fatigue, fever Orange Staining of body fluids Urine, tears, sweat Itching Rash Evaluate the Rash Where is it? What does it look like? Does it itch? When did it start? Has it spread? What makes it better or worse? Have you had an insect bite? 14
15 Other Possible Causes Insect bites Scabies Contact dermatitis Question patient about new soaps, lotions, perfumes, laundry detergents, etc Sunburn Dry skin Other drugs, especially new agents Viral or fungal infections Mild Rash Common Often resolve after first several weeks of treatment Usually do not require stopping medication Treated symptomatically with Benadryl, other antihistamines, low-dose prednisone 15
16 Drug Rash Usually begins on chest and later spreads to upper arms and thighs Itches Maculopapular Urticaria/hives Occurs and worsens after medications May be associated with more severe symptoms of airway compromise, angioedema, etc. Hold medications until reaction resolves May have to modify the drug regimen Managing & Monitoring Rifampin Monitor CBC monthly Advise women using hormonal contraceptive to use another form of control Reduction of methadone almost to an ineffective level Cannot use with some Antiretroviral drugs 16
17 Rifabutin Decreased WBC Decreased Platelet count Renal Impairment Hyperpigmentation Flushing G.I. upset Uveitis Eye pain/ irritation Arthralgias Joint pain Uveitis When given in higher doses with drugs that decrease renal clearance Hold Rifabutin until symptoms resolve Consider referral to ophthalmologist to rule-out other cause If infection is ruled-out, steroid eye drops may be used If recurring uveitis, stop rifabutin 17
18 Ethambutol Nausea Vomiting Loss of appetite Fever Headaches Dizziness Rash Changes in visual acuity Changes in red/green color discrimination Managing & Monitoring EMB Baseline & monthly visual acuity test (Snellen chart) Baseline & monthly color discrimination test (Ishihara tests) Question pt regarding possible visual disturbances including blurred vision. Observe children for eye rubbing, excessive blinking, sitting close TV, difficulty with accurate grasping Hold Rx Refer for Ophthalmologic evaluation Permanent vision impairment if Rx continued 18
19 Ophthalmic Toxicity 21 year old male arrested and incarcerated in county jail in February. After being incarcerated for 3 months he began to complain of fever, chills, productive cough, chest pain, night sweats, and weight loss. On October 7, five months after onset of symptoms, he continued to complain of previous symptoms. He was finally evaluated, CXR showed left upper lobe cavitary infiltrate, AFB smear (+) 1-10 per high power field. He was diagnosed with pulmonary TB. On October 12, he was started on the standard 4 drug therapy. The isolate was reported as isoniazid and streptomycin resistant. Pt. was improving, he was afebrile, had 6 lb wt. gain, night sweats had resolved, cough was improving. INH discontinued once susceptibilities were known, and he continued on RIF, PZA, EMB to complete 9 months of adequate therapy. Case Study #2- Opthalmic Toxicity After reviewing this case study, identify what should have been done differently in diagnosing this patient? Could have been diagnosed earlier, 5 months ago Should have been screened for TB TST Symptom review Baseline CXR If prior exposure, identify if patient had preventative treatment 19
20 Case Study # 2 Opthalmic Toxicity What Toxicities is a patient on EMB at risk for? Optic Neuritis Decreased visual acuity Decreased red-green color discrimination Case Study #2: Ophthalmic Toxicity What baseline testing should you do for your patient who is starting EMB? Visual Acuity (Snellen) Color Discrimination (Ishihara) 20
21 Case Study #2 - Ophthalmic Toxicity In March, 5 months after start of treatment, patient started c/o difficulty driving and reading road signs. As a provider managing this patient s anti-tb therapy, what would you do? Stop the EMB Refer to the Opthalmologist Case Study #2 - Ophthalmic Toxicity Called his nurse by phone, she instructed him to see his eye doctor. On March 21 he was seen by optometrist and given RX for corrective lenses. EMB continued 21
22 Case Study # 2 - Ophthalmic Toxicity On May 3 (7 months on anti-tb therapy) he again complains of worsening vision. Nurse finally assesses his vison. Baseline visual acuity in October was 20/20 both eyes, follow up visual acuity was now 20/200 in both eyes even with corrective lenses. On May 5 the EMB discontinued; continued on RIF, PZA and Levo added to regimen to complete 9 mo of treatment and referred to a retinal specialist. Ophthalmic Toxicity Follow-up Seen by retinal specialist in May and June DX: EMB optic neuropathy Central scotoma on right and parascotoma on left Vision uncorrected: 20/200 Nurse admitted to not performing visual acuity screening (Snellen chart), she only did color discrimination testing (Ishihara plates) 22
23 Pyrazinamide GI Upset Nausea Vomiting, Loss of appetite Rash Hepatotoxicity Arthralgias Joint pain Muscle Aches Gout (rare) Myalgias/Arthralgias If acute swelling, erythema, warmth present, evaluate for infection, gout PZA causes asymptomatic increase in uric acid, but rarely causes gout except in patients with pre-existing gout or decreased renal function NSAIDS often helpful in relieving discomfort Usually not necessary to discontinue medications 23
24 Second-line Drugs Cycloserine Ethionamide Levofloxacin Moxifloxacin PAS Streptomycin Amikacin Kanamycin Capreomycin Second-Line Drugs Amikacin Local Pain at injection site Rash Renal Toxicity Ototoxicity Vestibular Toxicity Electrolyte abnormalities (hypokalemia, hypomagnesemia) Capreomycin Local Pain at injection site Rash Renal Toxicity Ototoxicity Vestibular Toxicity Electrolyte abnormalities (hypokalemia, hypocalcemia, hypomagnesemia) 24
25 Auditory Toxicity Perform audiometry & vestibular screening Baseline Repeat monthly Identify pre-existing hearing loss Refer for evaluation if any decrease from baseline Vestibular Toxicity Vestibular toxicity monitoring Baseline and monthly vestibular screen Assess Hearing: fullness, stuffiness, unusual noises, hearing loss Dizziness, unsteadiness, giddiness, lightheadedness, floating sensation 25
26 Second-Line Drugs Levofloxacin, Moxifloxacin, Gatifloxacin Rash GI upset Mild CNS toxicity Photosensitivity EKG abnormalities Arthralgias Tendon rupture (rare) Ethionamide Rash GI upset Hepatotoxicity Endocrine effects Peripheral neuropathy Second-Line TB Drugs Cycloserine -Rash - CNS toxicity, may include seizure, depression, suicidal ideation, psychosis - Peripheral neuropathy - Skin changes (lichenoid eruptions, Stevens- Johnson Syndrome) Para-Aminosalicylate (PAS) -Rash - GI upset, may be significant - Hepatotoxicity - Reversible hypothyroidism Clofazimine -Rash -GI upset - Discoloration and dryness of skin - Photosensitivity - Retinopathy Linezolid -Rash - Myelosuppression - Nausea and diarrhea - Optic neuropathy - Peripheral neuropathy 26
27 Essential Monitoring Components Establish and Maintain a good a Provider Patient relationship Have a Case management plan Ongoing patient education Ongoing toxicity monitoring THEY ALWAYS COME BACK Do It Right The First Time! Barbara Seaworth, MD Medical Director, Heartland 27
28 Thank You! Questions? 28
TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects
TB Nurse Case Management San Antonio, TX April 1 3, 2014 TB Medications and Adverse Effects Debbie Onofre RN, BSN Nurse Consultant/ Nurse Educator Heartland National TB Center April 1, 2014 Debbie Onofre,
More informationTB Nurse Case Management
TB Nurse Case Management San Antonio, Texas March 2-4, 2011 TB Medications and Adverse Effects Debbie Onofre, RN, BSN March 3, 2011 Debbie Onofre, RN, BSN has the following disclosures to make: No conflict
More informationDebbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Monitoring Patients for TB Adverse Reactions and Managing Side Effects Catalina Navarro, RN, BSN April 11, 2014 Catalina Navarro, RN,
More informationAnti Tuberculosis Medications: Side Effects & adverse Events
Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 TB Medications and Adverse Drug Events Presented by Evelyn Drzymala, RN, BSN February 11, 2015 Evelyn Drzymala, RN, BSN has
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationManaging the Patients Response to TB Treatment
Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationMedication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Medication Administration and Adverse Reactions Alisha Blair, LVN September 28, 2011 Alisha Blair, LVN, has the following disclosures to make:
More informationTuberculosis medications: adverse drug reactions
Tuberculosis medications: adverse drug reactions Rajesh M. Prabhu, M.D. Infectious Diseases Essentia Health, Duluth, MN July 25, 2017 2014 MFMER slide-1 No Finanial Disclosures Learning Objectives 1. Describe
More informationShu-Hua Wang, MD, MPH &TM Assistant Professor of Medicine The Ohio State University
Shu-Hua Wang, MD, MPH &TM Assistant Professor of Medicine The Ohio State University For anti-tuberculosis medications: Describe clinical monitoring for adverse drug reactions Review specific drug side
More informationTreatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27
TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS Treatment: First Line Drugs 1. ISONIAZID = INH Bacteriocidal against dividing organisms Dose = 300mg = one pill = well absorbed Good CNS penetration Can be
More informationManaging and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Iris Barrera,
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:
More informationDrug Side Effects and Toxicity
Drug Side Effects and Toxicity Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Toxicity Nausea and vomiting Any Drug Can Cause
More informationStandard TB Treatment
Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationDana G. Kissner, MD Detroit Department of Health & Wellness Promotion Wayne State University
Dana G. Kissner, MD Detroit Department of Health & Wellness Promotion Wayne State University I reply to those who urge me to take medicine that they should wait at least until I am restored to my strength
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationPeter Mere Latham English physician & educator
Poisons and medicine are oftentimes the same substance given with different intents Dana G. Kissner, MD Detroit Department of Health & Wellness Promotion Wayne State University Peter Mere Latham 1789-1875
More informationTB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline
TB Grand Rounds Reynard McDonald, MD & Henry Fraimow, MD January 30, 2007 Outline Overview of 2006 ATS statement regarding hepatotoxicity of anti-tb therapy Case examples highlighting management of patients
More informationTreatment and Monitoring
Treatment and Monitoring Disclosures We have no actual or potential conflicts of interest in relation to this presentations. We have no financial relationships to disclose. Learning Objectives After this
More informationDRUG SIDE EFFECTS AND TOXICITY
DRUG SIDE EFFECTS AND TOXICITY Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Objectives After participating in this lecture,
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationAt the end of this session, participants will be able to:
Advanced Concepts in Pediatric TB: Treatment of Tuberculosis Disease Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [with help from Andrea Cruz, M.D.] Objectives At the end
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Adverse Drug events With Anti Tuberculosis Therapy What Every GP Should Know Authors: Kavitha Saravu, MD, DNB, DTM&H; Madhukar Pai, MD, PhD Standards of TB Care in India
More informationAntimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018
Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million
More informationPediatric TB Intensive San Antonio, Texas October 14, 2013
Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following
More informationManaging MDR TB Treatment Side Effects
Managing MDR TB Treatment Side Effects Barbara J. Seaworth, M.D. Medical Director Heartland National TB Center Pacific Islands TB Controllers Association Conference, September 14, 2017 Honolulu, Hawaii
More informationTuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats
Tuberculosis Facts Below are frequently asked questions about TB, and their answers. If you have additional questions you may contact the City of Ennis Department of Health Services at 972-875-1234 or
More informationTB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015
TB Nurse Assessment Ginny Dowell, RN, BSN October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19-22, 2015 Wichita, KS EXCELLENCE EXPERTISE INNOVATION Ginny Dowell,
More informationDrug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment
Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationLTBI in Special Populations John Nava, MD October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John
More informationAnti Tuberculosis Medications
Anti Tuberculosis Medications Mary Ann Rodriguez, MD March 8, 2017 TB Nurse Case Management March 7 9, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Mary Ann Rodriguez, MD has the following disclosures
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationOfficial ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016)
Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016) APPENDIX C: DRUGS IN CURRENT USE The U.S. Food and Drug Administration (FDA) has approved
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationDiagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
More informationDisclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t
Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations
More informationAntituberculous Agents
Antituberculous Agents Primary or First Line Drugs: Isoniazid (INH) Rifampin Rifadin or Rimactane Ethambutal Streptomycin Pyrazinamide Isoniazid(INH) Most active. Small molecule, water soluble, Structurally
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationDose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016
Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures
More informationPROBLEMS IN TX CASE STUDY. JB is a 42 yo BM who was admitted to
Why TB Drugs Fail Part 2 Why TB Drugs Fail OR How We Fail TB Drugs (and Tb Patients) 1 PROBLEMS IN TX FAILURE TO RESPOND TB MENINGITIS RENAL FAILURE HEPATITIS CAN T SWALLOW PILLS GI INTOLERANCE ADVERSE
More informationMANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo
MANAGEMENT OF DILI in TB/HIV coinfected patients Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo ANTI-TB drugs Groups Drugs Group 1: First-line oral drugs Ethambutol (Emb) Pyrazinamide(PZA) Isoniazid (INH)
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society
More informationTreatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1
Treatment of Tuberculosis Some Highlights of Most Recent Update Treatment of Tuberculosis Disease Germaine Jacquette, MD Physician Specialist NJMS Global Tuberculosis Institute September 15, 2010 The provider
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationAmarillo Surgical Group Doctor: Date:
Office Visit Information (General Surgery) Amarillo Surgical Group Doctor: Date: Patient s Information Name: Last First Middle Social Security #: Date of Birth: Age Gender: [ Male / Female ] Marital Status:
More informationPatient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD
Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986
More informationDR-TB Patient Treatment Log Book
REPUBLIC OF KENYA MINISTRY OF HEALTH DR-TB Patient Treatment Log Book Patient Name: Patient Reg. No.: VERSION 2016 DR-TB treatment outcome summary Outcome Mark one Date Cured Died Failed Defaulted Transferred
More informationTB Drugs. Discuss the common route for transmission of the disease. Discusses the out line for treatment of tuberculosis.
TB Drugs Red : important Black : in male / female slides Pink : in female s slides only Blue : in male s slides only Females doctor notes Grey: Males doctor notes OBJECTIVES: By the end of this lecture,
More informationTips and Tricks for Diagnosing and Treating Tuberculosis
Tips and Tricks for Diagnosing and Treating Tuberculosis Bob Belknap M.D. Director, Denver Metro TB Program December 6, 2017 DenverPublicHealth.org @DenverPublicHealth @DenPublicHealth Disclosures No conflicts
More informationNURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)
NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet) ASSESSMENT Prior to administration: Obtain complete health history including allergies, drug history, and possible drug interactions.
More informationTuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)
Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationLatent TB Infection Treatment
Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None
More informationMDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationPlease describe, in detail, when the symptoms began:
161 East Mallard Drive, Suite 130, Boise, ID 83706 (208) 947-0100 New Patient Intake Patient Name: Primary Care Physician: Date: Email address: How did you hear about AVT (mark all that apply) Online On
More informationTB Case Management Hepatitis
TB Case Management Hepatitis Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment
More informationAnti-Tuberculosis Drugs
Tuberculosis in Nursing: Prevention, Treatment, and nfection Control Curry nternational Tuberculosis Center Anti-Tuberculosis Drugs What Nurses Need to Know Objectives Describe the anti-tb medications
More informationTB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:
TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationPatient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio
927 W. Myrtle St. Boise, ID 83702 (208) 947-0100 NEW PATIENT INTAKE Patient Name: Date: Email Address: Primary Care Physician: How did you hear about AVT? (Please mark all that apply) Online Website On
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationHeadache Follow-up Visit Form
!1 Headache Follow-up Visit Form We will be unable to see you unless this form is completely filled out. We appreciate your thoroughness. Name DOB Age Today s Date Referring doctor: Primary doctor: Neurologist:
More informationPharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
More informationTuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18
Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationManagement of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015
Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Catalina Navarro,
More informationAdvanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014
Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 TB Drugs David Griffith, MD August 13, 2014 David Griffith, MD has the following disclosures to make: No conflict
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationTB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION
TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More informationJoseph S. Weiner, MD, PC Patient History Form
Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:
More informationHASPI Medical Biology Lab 03
Patient 1001 is a 42-year-old female that is experiencing severe heartburn, abdominal pain, bloating, nausea, and vomiting. Ulcers Bleeding sores in the stomach or intestine Gallbladder Disease Gallstones
More informationCase presentation. Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD
Case presentation Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD History of presenting illness 20 Year old woman from Nigeria who came to study at Montgomery in August 2013 About 2 weeks after arriving,
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationMEDICAL MANAGEMENT OF TB
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE MEDICAL MANAGEMENT OF TB LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the recommended treatment
More information